Zealand Pharma Reports Positive Phase 1a Results for Novel Kv1.3 Channel Blocker ZP9830 in Autoimmune Disease Development
核心洞察
Zealand Pharma announced positive Phase 1a single ascending dose results for ZP9830, a potent and selective Kv1.3 (搜索) channel blocker designed to treat immune-mediated inflammatory diseases (搜索).
The first-in-human trial demonstrated favorable safety and tolerability with no serious adverse events, dose-limiting safety findings, or clinically relevant safety concerns observed across all dose levels.
ZP9830 exhibited dose-proportional pharmacokinetics with very high bioavailability and showed robust, dose-dependent pharmacodynamic activity consistent with Kv1.3 (搜索) target engagement.
Zealand Pharma A/S announced positive topline results from the Phase 1a single ascending dose (SAD) portion of its first-in-human trial evaluating ZP9830, a novel Kv1.3 (搜索) channel blocker targeting immune-mediated inflammatory diseases (搜索). The randomized, double-blind, placebo-controlled study demonstrated favorable safety, tolerability, and pharmacokinetic profiles that align with the company's expectations for this differentiated immunological therapy.
Safety and Tolerability Profile
The Phase 1a trial showed ZP9830 was well tolerated across all investigated dose levels, with no dose-limiting safety findings or other safety concerns observed. All treatment-emergent adverse events (TEAEs) were non-serious and mild in severity. The study found no clinically relevant safety findings in vital signs, 12-lead electrocardiogram (ECG) recordings, physical examinations, or safety laboratory parameters.
"We are very pleased with the Phase 1a single ascending dose results, which demonstrated favorable safety and tolerability, and a PK/PD profile consistent with our expectations for a highly differentiated, immunological therapy with a novel mechanism of action," said David Kendall, MD, Chief Medical Officer of Zealand Pharma.
Pharmacokinetic and Pharmacodynamic Results
ZP9830 exhibited pharmacokinetic parameters that increased in a dose-proportional manner across the investigated dose range. Data from the intravenous cohort indicated very high bioavailability of the subcutaneous formulation. Exploratory pharmacodynamic biomarkers showed robust, dose-dependent activity consistent with Kv1.3 (搜索) target engagement, providing early confirmation that ZP9830 affects immune cell biology as intended.
Trial Design and Methodology
The first-in-human single ascending dose study (ClinicalTrials.gov ID: NCT06682975) was conducted in healthy male participants to investigate the effects of single ascending doses of ZP9830 administered subcutaneously across a wide dose range, as well as intravenously at one dose level. The main objectives were to assess safety, tolerability, and pharmacokinetics, with proof of mechanism as an additional exploratory objective. The SAD portion included a suitable pharmacological model to explore immunomodulatory activity.
Mechanism of Action and Therapeutic Potential
ZP9830 is a potent and selective Kv1.3 (搜索) channel blocker with potential to treat a broad range of immune-mediated inflammatory diseases (搜索). Kv1.3 is a potassium ion channel that is selectively upregulated on effector memory T cells, which play a central role in autoimmunity and chronic inflammation through the release of pro-inflammatory cytokines that drive tissue damage.
The anti-inflammatory effects of Kv1.3 (搜索) channel blockade have been demonstrated in preclinical models of immunological disorders. The selective expression of Kv1.3 on effector memory T cells makes it an attractive therapeutic target, as inhibition is expected to preserve the protective functions of the broader immune system.
Development Timeline
The development program is progressing rapidly and as planned. The multiple ascending dose (MAD) part of the Phase 1a trial is ongoing and is evaluating the effects associated with extended exposure to ZP9830. Zealand Pharma expects Phase 1a multiple ascending dose data and Phase 1b/2a initiation in the second half of 2026.
Kendall emphasized that these data "underscore the strength of Zealand Pharma's proprietary peptide engineering capabilities in addressing historically challenging targets and further reinforce our confidence in ZP9830 as a promising Kv1.3 (搜索) channel blocker with potential in multiple autoimmune and inflammatory diseases (搜索) with unmet medical need."